An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
Status:
Completed
Trial end date:
2017-06-07
Target enrollment:
Participant gender:
Summary
This study consisted of 2 parts: a double-blind (DB) phase and an open-label extension (OLE)
phase. Only the OLE phase is described in this record. The OLE phase was a safety study. All
participants received GWP42003-P initially titrated to 20 milligrams (mg)/kilograms (kg)/day;
however, investigators subsequently decreased or increased the participant's dose to a
maximum of 30 mg/kg/day (no minimum).